Abstract
<h3>Background</h3> Bispecific antibodies (BsAbs) are gaining momentum in several immunotherapeutic<sup>1 2 3</sup> and immuno-oncology settings.<sup>4</sup> Certain designs of BsAbs enable tumor-specific targeting when two targets are concurrently expressed on tumor...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
